Dr Su Han Lum
Dr Geoff Shenton
Professor Sophie Hambleton
Professor Andrew Gennery
Professor Mary Slatter
et al. | Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+ T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts | 2024 |
|
Dr Zohreh Nademi
Dr Geoff Shenton
Helen Watson
Emma Matthews
Kay Carruthers
et al. | CD3+TCRαβ/CD19+-depleted stem cell boost and CD45RO+ memory T-cell add-back as a successful salvage treatment for poor graft function unresponsive to eltrombopag, following a second allogenic HSCT | 2024 |
|
Professor Marieke Emonts-le Clercq
Ashley Bell
Kathryn Bell
Dr Daniel Fabian
Professor John Isaacs
et al. | Adeno-associated virus 2 infection in children with non-A–E hepatitis | 2023 |
|
Dr Peter Carey
Dr Scott Marshall
Dr Geoff Shenton
Dr Tina Biss
Professor Roderick Skinner
et al. | Allogenic haematopoeitic stem cell transplant as cure for severe transfusion-dependent non-dominant hereditary spherocytosis due to homozygous SPTA1 mutation | 2023 |
|
Dr Frederik van Delft
Professor Simon Bailey
Professor Roderick Skinner
Dr Geoff Shenton
Dr Peter Carey
et al. | Unusual relapse of low hypodiploid acute lymphoblastic leukaemia in a family with Li-Fraumeni syndrome | 2023 |
|
Dr Hannah Tumelty
Dr Geoff Shenton
Dr Malcolm Brodlie
| Are trough tobramycin concentrations taken from a central venous catheter accurate enough to safely use? | 2022 |
|
Dr Tobias Menne
Professor Julie Irving
Professor Ruth Plummer
Dr Geoff Shenton
Professor Gareth Veal
et al. | Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial | 2022 |
|
